Floatz logo

rc48

RC48

Sun Yat-sen Universityantibody_drug_conjugatePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the RC48 cohort.

Asset / SponsorPhaseRating
Carboplatin
Sun Yat-sen University
Phase 2CCC
Tislelizumab
Sun Yat-sen University
Phase 2CCC

Same molecule, other indications

rc48 is also rated in:

non-small cell lung carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →
Disitamab VedotinDormant
CCC
Indicative ·
53 / 100
View asset →
ERBB2 Mutation-Related TumorsDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →